The finding of an elevated serum activin B level also raises the possibility that treatment with follistatin may be of value in the management of patients with CFS/ME, since follistatin, in addition to blocking the actions of activin A, also can block the actions of activin B. Further, treatment with follistatin has the potential advantage that in addition to attenuating the actions of the activins, it can also block the actions of myostatin, thus enhancing muscle mass [34]. Here, MSTN is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.